Collegium Pharmaceutical (COLL) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Nov, 2026Executive summary
Record Q3 net product revenue of $216.3M, up 3% YoY; ADHD products contributed more than 36% of revenue, while the pain portfolio generated $138.0M.
JORNAY PM reached record revenue, prescription and prescriber levels; AZSTARYS generated $26.5M in its first full quarter under new ownership.
Growth in JORNAY PM and AZSTARYS was partly offset by lower NUCYNTA and XTAMPZA ER revenue; adjusted EBITDA fell 9% YoY to $121.6M.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Collegium Pharmaceutical
- Record 2023 results underpin 2024 growth, debt repayment and shareholder returns.COLL
Q4 2023 - ADHD and pain portfolios drive 8% revenue growth, with strong cash flow fueling expansion.COLLH.C. Wainwright 28th Annual Global Investment Conference
- Diversification into ADHD and disciplined growth strategies position the business for sustained expansion.COLLMorgan Stanley 24th Annual Global Healthcare Conference
- Q2 2026 revenue rose 6% on ADHD and AZSTARYS gains, but net loss followed higher expenses.COLLQ2 2026
- Strong growth and portfolio durability expected, with expanded ADHD presence post-AZSTARYS.COLLJefferies Global Healthcare Conference 2026
- Q1 2026 revenue up 9% with AZSTARYS acquisition set to boost ADHD and pain portfolios.COLLQ1 2026
- ADHD franchise growth and AZSTARYS deal drive 2026 outlook, with stable pain portfolio performance.COLL25th Annual Needham Virtual Healthcare Conference
- Q1 2025 revenue up 23% to $177.8M, driven by ADHD and pain portfolio growth.COLLQ1 2025
- Record 2024 revenue and EBITDA, with Jornay PM and pain portfolio fueling double-digit growth.COLLQ4 2024